ImmuCell (id:5867 ICCC)
3.69 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 11:54:53 PM)
Exchange closed, opens in 9 hours 35 minutes
About ImmuCell
Market Capitalization 32.88M
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Headquarters (address) |
56 Evergreen Drive Portland 04103 ME United States |
Phone | 207 878 2770 |
Website | https://immucell.com |
Employees | 75 |
Sector | Healthcare |
Industry | Biotechnology |
Ticker | ICCC |
Exchange | NASDAQ Stock Exchange |
Currency | USD |
52 week range | 3.34 - 5.59 |
Market Capitalization | 32.88M |
P/E forward | -33.55 |
Price/Sale | 1.42 |
Price/Book | 1.14 |
Beta | 0.567 |
EPS | -0.490 |
EPS United States (ID:6, base:3404) | 24.21 |